6533b827fe1ef96bd1285e25
RESEARCH PRODUCT
Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.
G SterrantinoM ZaccarelliG ColaoF BaldantiS Di GiambenedettoT CarliF MaggioloM ZazziA GiacomettiL ButiniR Del GobboP BagnarelliD TacconiG CorbelliS ZanussiL MonnoG PunziF MaggioloA CallegaroL CalzaMc ReR PristeraP TurconiA MandasS TiniA ZoncadaE PaoliniG AmadioL SighinolfiG ZuccatiM MorfiniR ManettiP CorsiL GalliM Di PietroF BartalesiG ColaoA TostiA Di BiagioM SettiB BruzzoneA Di BiagioG PencoM TrezziA OraniR PardelliI ArcidiaconoA DegiuliM De GennaroA ChioderaA ScalziniL PalvariniP AlmiG TodaroP CicconiS RusconiMr GismondoV MicheliBiondi MlN GianottiA CapettiP MeravigliaE BoeriC MussiniM PecorariA SoriaL VecchiAo GerardoM SantirocchiD BrustiaAo MaggioreP RavaniniFd BelloN RomanoSalvatrice MancusoC CalzettiR MaseratiG FiliceF BaldantiD FrancisciG ParrutiE PolilliD SacchiniC MartinelliR ConsoliniL VatteroniA VivarelliA NerliL LenziG MagnaniP OrtolaniM AndreoniG PalamaraC FimianiL PalmisanoS Di GiambenedettoM ColafigliV VulloO TurrizianiM MontanoA AntinoriC DentoneA GonnelliA De LucaM ZazziM PalumboV GhisettiS BonoraPd FoglieC RossiV MondinoM MalenaP GrossiE SeminariF. Polettisubject
MaleTime FactorsCross-sectional studyHuman immunodeficiency virus (HIV)Drug ResistanceHIV InfectionsDrug resistancemedicine.disease_causeCohort StudiesAntiretroviral Therapy Highly ActiveRitonavir-boosted darunavirGenotypeHIV InfectionTreatment FailureViralGenotypic resistanceDarunavirSulfonamidesGeneral MedicineMiddle AgedVirological failureInfectious DiseasesFemaleHumanmedicine.drugAdultMicrobiology (medical)Logistic ModelTime FactorGenotypeAntiretroviral TherapySettore MED/17 - MALATTIE INFETTIVESulfonamideDrug Resistance ViralmedicineHumansHighly ActiveDarunavir; Genotypic resistance; Protease inhibitors; Ritonavir-boosted darunavir; Adult; Antiretroviral Therapy Highly Active; Cohort Studies; Cross-Sectional Studies; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Male; Middle Aged; Mutation; Sulfonamides; Time Factors; Treatment Failure; Drug Resistance Viral; Microbiology (medical); Infectious DiseasesHIV Protease InhibitorDarunavirCross-Sectional Studiebusiness.industryHIV Protease InhibitorsProtease inhibitorsAntiretroviral therapyVirologyCross-Sectional StudiesLogistic ModelsProtease inhibitorMutationGenotypic resistanceHIV-1Cohort Studiebusinessdescription
Introduction: This study aimed at defining protease (PR) resistance mutations associated with darunavir (DRV) failure and PR resistance evolution at DRV failure in a large database of treatment-experienced human immunodeficiency virus (HIV) patients. Results: Overall, 1,104 patients were included: 118 (10.7%) failed at a median observation time of 16 months. The mean number of PR mutations at baseline was 2.7, but it was higher in patients who subsequently failed DRV. In addition, the number of PR mutations increased at failure. The increase in the mean number of mutations was completely related to mutations considered to be associated with DRV resistance following the indications of the main DRV clinical trials. Discussion The higher statistical difference at baseline between failing versus non-failing patients was observed for the V32I and I84V mutations. At DRV failure, the major increase was still observed for V32I; I54L, V11I, T74P and I50V also increased. Despite the increment in the mean number of mutations per patient between baseline and failure, in 21 patients (17.8%) at baseline and 36 (30.5%) at failure, no PR mutation was detected. Conclusion: The HIV-DB interpretation algorithm identified few patients with full DRV resistance at baseline and few patients developed full resistance at DRV failure, indicating that complete resistance to DRV is uncommon. © Springer-Verlag 2011.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2012-01-01 |